Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
99mTc-1-thio-D-glucose SPECT/CT and 18F-FET PET/CT in Glioma
NCT07475390Active, not recruiting
- Sponsor
- Tomsk National Research Medical Centre of the Russian Academy of Sciences
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Open-label, single-arm trial of 99mTc-1-thio-D-glucose and O-(2-[18F]fluoroethyl)-L-tyrosine in glioma, sponsored by Tomsk National Research Medical Centre of the Russian Academy of Sciences. Primary endpoints: 99mTc-1-thio-D-glucose uptake in tumor (SUVmean) at 1 hour, 99mTc-1-thio-D-glucose uptake in background (SUVmean) at 1 hour and 6 more. Started Feb 2026; status: active, not recruiting.
02
Drugs
99mTc-1-thio-D-glucoseO-(2-[18F]fluoroethyl)-L-tyrosine
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07475390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07475390.